PATENT COOPERATION TREATY 09/142326

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

United States Patent and Trademark Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 06 January 1998 (06.01.98)	
International application No. PCT/US97/03584	**Applicant's or agent's file reference** ISIS-2425
International filing date (day/month/year) 07 March 1997 (07.03.97)	**Priority date** (day/month/year) 08 March 1996 (08.03.96)
Applicant NIELSEN, Peter, E. et al	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

08 October 1997 (08.10.97)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO **34, chemin des Colombettes** **1211 Geneva 20, Switzerland**	Authorized officer M. Abidine
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

Form PCT/IB/331 (July 1992)

1824809

Copy for the receiving Office (RO/US)

09/142,[illegible] PCT/US97/03584

PATENT COOPERATION TRE[illegible]Y

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and Administrative Instructions, Section 422)

To:

CALDWELL, John, W.
Woodcock Washburn Kurtz Mackiewicz & Norris L.L.P.
46th floor
One Liberty Place
Philadelphia, PA 19103
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)
07 January 1998 (07.01.98)

Applicant's or agent's file reference
ISIS-2425

IMPORTANT NOTIFICATION

International application No.
PCT/US97/03584

International filing date (day/month/year)
07 March 1997 (07.03.97)

1. The following indications appeared on record concerning:

[X] the applicant [ ] the inventor [ ] the agent [ ] the common representative

Name and Address
ISIS PHARMACEUTICALS, INC.
2280 Faraday Avenue
Carlsbad, CA 92008
United States of America

State of Nationality: US
State of Residence: US
Telephone No.:
Facsimile No.:
Teleprinter No.:

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

[ ] the person [ ] the name [X] the address [ ] the nationality [ ] the residence

Name and Address
ISIS PHARMACEUTICALS, INC.
2292 Faraday Avenue
Carlsbad, CA 92008
United States of America

State of Nationality: US
State of Residence: US
Telephone No.:
Facsimile No.:
Teleprinter No.:

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

[X] the receiving Office
[ ] the International Searching Authority
[X] the International Preliminary Examining Authority
[ ] the designated Offices concerned
[X] the elected Offices concerned
[ ] other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer
M. Abidine

Telephone No.: (41-22) 338.83.38

Form PCT/IB/306 (March 1994)

001825170

Replaced by amendment Article 34

19

PATENT COOPERATION TREATY

PCT

REC'D 30 JUN 1998

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference ISIS-2425	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US97/03584	International filing date *(day/month/year)* 07 MARCH 1997	Priority date *(day/month/year)* 08 MARCH 1996
International Patent Classification (IPC) or national classification and IPC IPC(6): C12Q 1/68 and US Cl.: 435/6		
Applicant NIELSEN, PETER E.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets.

   [X] This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 7 sheets.

3. This report contains indications relating to the following items:

   I [X] Basis of the report

   II [ ] Priority

   III [ ] Non-establishment of report with regard to novelty, inventive step or industrial applicability

   IV [ ] Lack of unity of invention

   V [X] Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

   VI [ ] Certain documents cited

   VII [ ] Certain defects in the international application

   VIII [X] Certain observations on the international application

Date of submission of the demand	Date of completion of this report
08 OCTOBER 1997	22 MAY 1998
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer KARDIN MARSCHEL Telephone No. (703) 308-0196

Form PCT/IPEA/409 (cover sheet) (January 1994)*

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US97/03584

I. Basis of the report

1. This report has been drawn on the basis of *(Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments)*:

☐ the international application as originally filed.

☒ the description, pages 1-31 , as originally filed.
pages NONE , filed with the demand.
pages NONE , filed with the letter of _____.
pages _____ , filed with the letter of _____.

☒ the claims, Nos. NONE , as originally filed.
Nos. NONE , as amended under Article 19.
Nos. 1-21 , filed with the demand.
Nos. NONE , filed with the letter of _____.
Nos. _____ , filed with the letter of _____.

☒ the drawings, sheets/~~fig~~ 1-2 , as originally filed.
sheets/~~fig~~ NONE , filed with the demand.
sheets/~~fig~~ NONE , filed with the letter of _____.
sheets/~~fig~~ _____ , filed with the letter of _____.

2. The amendments have resulted in the cancellation of:

☒ the description, pages NONE.

☒ the claims, Nos. NONE.

☒ the drawings, sheets/~~fig~~ NONE.

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the ~~Supplemental Box~~ Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US97/03584

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. STATEMENT

Novelty (N)	Claims	1-9 and 11-21	YES
	Claims	10	NO
Inventive Step (IS)	Claims	20	YES
	Claims	1-19 and 21	NO
Industrial Applicability (IA)	Claims	1-21	YES
	Claims	NONE	NO

2. CITATIONS AND EXPLANATIONS

Claim 10 lacks novelty under PCT Article 33(2) as being anticipated by Christensen et al., Buchardt et al. (WO 92/20702), and Buchardt et al. (WO 92/20703). Christensen et al. describes the monomers of instant claim 10 on page 181, second column, lines 15-18. Buchardt et al. (WO 92/20702) describes the monomers of instant claim 10 at page 8, line 19, through page 9, line 5, with bulky groups attached to monomer bases being described at page 19, lines 9-14. Buchardt et al. (WO 92/20703) describes the monomers of instant claim 10 at page 11, lines 20-43, with bulky groups attached to monomer bases being described at page 15, line 36, through page 16, line 4.

Claims 1-19 and 21 lack an inventive step under PCT Article 33(3) as being obvious over either of Buchardt et al. (WO 92/20702) or Buchardt et al. (WO 92/20703) taken in view of Klevan et al. Buchardt et al. (WO 92/20702) describes PNA polymers with reporter ligands as L groups in claim 3-5 therein including backbone variable length alkyl spacers between the attachment sites of the L side groups on said backbone. These polymers including labels are additionally utilized with target nucleic acid recognition assays as described in claims 19-22 therein. Similarly, Buchardt et al. (WO 92/20703) describes PNA polymers being labeled and used in a mixture with target nucleic acid in hybridization assays on page 88, lines 7-13, with claims 2-3 therein describing reporter ligands for L groups. Both of these descriptions suggest and motivate labeled PNA polymer usage. The labels in these descriptions are radioactive labels. Klevan et al. describes the substitution of nonradioactive labels, such as biotin, by attachment to the bases of a probe that is used in a hybridization assay. These biotin attachments are bulky and are separated from the base by several atoms lengths or at least 1-3 atoms. Thus, it would have been obvious to the practitioner in the art at the time of the instant invention to practice the instant invention of claims 1-19 and 21 because the basic PNA probe polymers with labels are described as used in hybridization assays in the two Buchardt et al. descriptions and Klevan et al. describes, motivates, and suggests the substitution of biotin base labels in such assays for (Continued on Supplemental Sheet.)

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The intersubunit linkages of the PNA polymers lack enablement beyond these linkages resulting from either peptide type, vinyl type, or phosphodiester analog type linkages. The peptide type linkage is instantly described as to how to prepare it. The vinyl type and phosphodiester analog type linkages are well known in the art. It is noted that the monomers of instant claim 10 are linked into PNA polymers via peptide type linkage chemistry. Since complex base protection chemistry is required for the synthesis of PNA polymers the usage of other linkage types other than those described above lacks enablement in the instant description.

Claims 1-9 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because practice of the claimed invention is not enabled as required under PCT Rule 5.1(a) for the reasons set forth in the immediately preceding paragraph.

Instant claim 11 and those dependent therefrom require the structure (I) as shown in lines 2-3 of said claim 11. This structure terminates at the rightmost end with "D" groups which are alkyl chains which may be substituted. The linkage together of the monomers as described in instant claim 10 would only result in termini of the amino type and not the remaining selections for "D" beyond such termini. The instant description lacks any synthetic method by which alkyl "D" end termini would be prepared thus resulting in a lack of enablement for these termini beyond said amino containing "D" termini.

Claims 11-19 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because practice of the claimed invention is not enabled as required under PCT Rule 5.1(a) for the reasons set forth in the immediately preceding paragraph.

Supplemental Box
(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):
radioactive labels thus resulting in the bulky group feature of the instant invention and therefore the entire description of the instant invention via the combinations of descriptions of the two Buchardt et al. descriptions and the Klevan et al. description.

Claim 20 meets the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the carbon atom attachment of the L side chain with the amide bond in said side chain that is required in instant claim 20.

Claims 1-21 meet the criteria set out in PCT Article 33(4) as having industrial applicability.

——— NEW CITATIONS ———

NONE

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07H 21/00 — A1

(11) International Publication Number: **WO 97/32888**

(43) International Publication Date: 12 September 1997 (12.09.97)

(21) International Application Number: PCT/US97/03584

(22) International Filing Date: 7 March 1997 (07.03.97)

(30) Priority Data:
08/612,661 8 March 1996 (08.03.96) US

(60) Parent Application or Grant
(63) Related by Continuation
US 08/612,661 (CIP)
Filed on 8 March 1996 (08.03.96)

(71) Applicant *(for AM AZ BY KG KZ MD RU TJ TM only)*: ISIS PHARMACEUTICALS, INC. [US/US]; 2280 Faraday Avenue, Carlsbad, CA 92008 (US).

(71)(72) Applicant and Inventor: NIELSEN, Peter, E. [DK/DK]; Hjortevanget 509, DK-2980 Kokkedal (DK).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: CHRISTENSEN, Leif [DK/DK]; Hasselvaenget 50, DK-4300 Holbaek (DK). HANSEN, Henrik, Frydenlund [DK/DK]; Tarnvej, 33a, st, DK-2610 Radovre (DK).

(74) Agents: CALDWELL, John, W. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris L.L.P., 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: SUBSTITUTED NUCLEIC ACID MIMICS

(57) Abstract

Compositions and methods are provided for the nucleic acid mimic determination of nucleic acids. The compositions and methods may be used in the diagnosis and treatment of diseases amenable through modulation of nucleic acids which encode proteins that are implicated in disease states. In accordance with preferred embodiments, mimics are comprised of non-naturally occurring backbones to which are appended modified heterocyclics bases. Such bases preferably have sterically balky substituents 1, 2, or 3 atoms removed from the sites of attachment to the backbone.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	**GB**	United Kingdom	**MW**	Malawi
AT	Austria	**GE**	Georgia	**MX**	Mexico
AU	Australia	**GN**	Guinea	**NE**	Niger
BB	Barbados	**GR**	Greece	**NL**	Netherlands
BE	Belgium	**HU**	Hungary	**NO**	Norway
BF	Burkina Faso	**IE**	Ireland	**NZ**	New Zealand
BG	Bulgaria	**IT**	Italy	**PL**	Poland
BJ	Benin	**JP**	Japan	**PT**	Portugal
BR	Brazil	**KE**	Kenya	**RO**	Romania
BY	Belarus	**KG**	Kyrgystan	**RU**	Russian Federation
CA	Canada	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CF	Central African Republic			**SE**	Sweden
CG	Congo	**KR**	Republic of Korea	**SG**	Singapore
CH	Switzerland	**KZ**	Kazakhstan	**SI**	Slovenia
CI	Côte d'Ivoire	**LI**	Liechtenstein	**SK**	Slovakia
CM	Cameroon	**LK**	Sri Lanka	**SN**	Senegal
CN	China	**LR**	Liberia	**SZ**	Swaziland
CS	Czechoslovakia	**LT**	Lithuania	**TD**	Chad
CZ	Czech Republic	**LU**	Luxembourg	**TG**	Togo
DE	Germany	**LV**	Latvia	**TJ**	Tajikistan
DK	Denmark	**MC**	Monaco	**TT**	Trinidad and Tobago
EE	Estonia	**MD**	Republic of Moldova	**UA**	Ukraine
ES	Spain	**MG**	Madagascar	**UG**	Uganda
FI	Finland	**ML**	Mali	**US**	United States of America
FR	France	**MN**	Mongolia	**UZ**	Uzbekistan
GA	Gabon	**MR**	Mauritania	**VN**	Viet Nam

59 Rec'd PCT/PTO 04 SEP 1998
PCT/US97/03584
09/142326

SUBSTITUTED NUCLEIC ACID MIMICS

FIELD OF THE INVENTION

This invention is directed to the synthesis and use of nucleic acid mimics containing one or more heterocyclic base moieties substituted by chemical groups in order to diminish or prevent the formation of triplexes. This effect can be used to design antisense or probe reagents that avoid forming triplexes.

BACKGROUND OF THE INVENTION

In the art, there are known several nucleic acid mimics having nucleobases bound to backbones other than the naturally occurring ribonucleic acid or deoxyribonucleic acid backbones having the ability to bind to nucleic acids having a nucleobase sequence complementary to the base sequence of the nucleic acid mimic. Among these, only the peptide nucleic acids (PNA's) as described, for example, in WO 92/20702 have demonstrated a likelihood for potential use as therapeutic and diagnostic reagents. This may be due to their ability to bind nucleic acids (NAs) of complementary nucleobase sequence with a higher affinity than shown by the corresponding wild-type nucleic acid.

One of the unique properties of PNAs is their ability to form PNA_2-NA triplexes that are more stable than the corresponding PNA-NA duplexes. This ability can be used advantageously for various purposes including PCR clamping (WO 93/25706). However, there are some drawbacks for applications that require sequence selection, because such selection would be biased for triplex forming sequences. Therefore, there is a need for PNAs that do not form such triplexes.

OBJECTS OF THE INVENTION

It is an object of this invention to provide substituted nucleic acid mimics that do not preferentially form triplexes with nucleic acids.

It is a further object of this invention to provide methods for sequence selective determination of nucleic acids.

It is yet a further object of this invention to provide therapeutic, diagnostic and research reagents that can modulate the expression of nucleic acids which encode proteins suspected of causing or indicating the existence of a disease state.

BRIEF DESCRIPTION OF THE INVENTION

In accordance with this invention there are provided nucleic acid mimics containing one or more heterocyclic bases substituted by a sterically bulky substituent at a position which is 1, 2 or 3 atoms removed from the atom of the base which is attached to the backbone.

Further there are provided methods for disfavouring the formation of triplex structures comprising a nucleic acid strand and two strands of a nucleic acid mimic, having a base sequence complementary to the nucleic acid strand. Such methods include incubating a mixture of the nucleic acid and the nucleic acid mimic under conditions suitable for forming a nucleic acid/nucleic acid mimic duplex. The formation of triplexes is avoided by providing

sterically bulky substituents on the nucleic acid mimic which are located at positions that would be in close proximity to each other if bound to nucleic acid in a triplex.

In accordance with this invention there are provided methods for the determination of a nucleic acid by providing a nucleic acid mimic substituted at positions which are 1, 2 or 3 atoms removed from the atom of the base which is attached to the backbone. Said nucleic acid mimic is incubated with the nucleic acid under conditions suitable for the formation of a duplex between the nucleic acid mimic and the nucleic acid. The occurrence of the duplex is related to the identity or existence of the nucleic acid.

The present invention provides nucleic acid mimics for modulating the expression of nucleic acids that encode proteins which are suspected of producing a disease state in mammals. The nucleic acid mimics of this invention can be used in therapeutics, diagnostics and as research reagents.

One favourable aspect of this invention is that nucleic acid mimics substituted as described herein substantially retain the ability to form duplexes with good efficiency and discrimination comparable to the corresponding unsubstituted nucleic acid mimic.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic illustrating an exemplary synthesis of a PNA monomer containing cytosine substituted at the N^4 position.

Figure 2 is a schematic illustrating the Watson-Crick base pairing between N^4 substituted cytosine of a PNA and guanosine of a DNA.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with this invention, novel compounds are provided that are useful for disfavouring the formation of triplexes with nucleic acids. A nucleic acid mimic in accordance with the invention is a molecule having a

sequence of modified heterocyclic bases, preferably naturally occurring bases, *e.g.* those which occur in "wild-type" nucleic acids, bound to a non-naturally occurring backbone. The nucleic acid mimics bind to a nucleic acid having a complementary base sequence through base pairing.

Preferred nucleic acid mimics are molecules wherein the base moieties are bound to the backbone via an amine nitrogen atom of the backbone. Preferred backbone structures for the mimics are described in WO 92/20702, United States Patent application Serial No. 08/054,363, filed April 26, 1993, United States Patent application Serial No. 08/319,411, filed October 6, 1994 and United States Patent application Serial No. 08/366,231, filed December 28, 1994. The above-referenced disclosures are herein incorporated by reference.

Heterocyclic bases of the nucleic acid mimics of the present invention are heterocyclic moieties that are able to base pair with nucleobases of a nucleic acid by hydrogen bonding. In the case of triplex formation, two kinds of interactions are involved: Watson-Crick binding and Hoogsteen binding. The formation of triplexes between PNA and NA is described in WO 95/01370.

The term "heterocyclic moiety" or "heterocyclic base" includes the naturally occurring purine and pyrimidine nucleobases. For the purpose of this invention, the term "pyrimidine" refers to any 1,3-diazine irrespective of its substituents. The naturally occurring pyrimidine nucleobases are cytosine, thymine and uracil. Naturally occurring purine nucleobases include adenine and guanine. The term "heterocyclic moiety" or "heterocyclic base" also includes non-naturally occurring nucleobases. An example of a non-naturally occurring base is a base in which any of the ring atoms of the nucleobases is replaced by another atom. For example, CH may be replaced by N and *vice versa*. Such modifications can occur at more than one position. Another example of a non-naturally occurring base is a base in which the 2- and 4-substituents of a naturally occurring base are

reversed. Structures of naturally and non-naturally occurring pyrimidine bases are shown below (the third structure from the left is that of a non-naturally occurring pyrimidine base known as pseudo-isocytosine):



In the invention, the heterocyclic moiety is attached to the backbone at a specific ring position of the heterocycle. In the case of substituted naturally occurring nucleobases, this position is preferably occupied by a nitrogen atom. According to this invention, the sterically bulky substituent can be attached to the heterocyclic moiety at a position which is 1, 2 or 3 atoms removed from the position of attachment of the heterocyclic moiety to the backbone. In case of the pyrimidine bases, positions conventionally numbered as ring position 4, 5 and 6 are preferred. The 4-position is most preferred for attaching a bulky substituent. Some effect on triplex formation may also occur when the substituent is attached to the 5- and 6-positions, but in this case, the substituents should be sterically bulkier than substituents located at position 4. In the case of non-naturally occurring bases, positions corresponding to pyrimidine positions 4, 5 and 6 in their spatial orientation are also preferred. In case of substitution on the 5-position of a non-naturally occurring base, the triplex formation is pH dependent as it is for a naturally occurring base such as cytosine. Duplex formation is likely not effected by pH in any case.



Shown above are formulae of heterocyclic bases having substituents designated R. Each R can independently be H, -NO, $-NO_2$, $-SO_3$, -CN, -OH, -SH, $-PO_3^{2-}$, -COOH, -R', -F, -Cl, -Br, -I, -O-R', -S-R', $-N(R')_2$, $-C(R')^3$, -C(=X)(R'), C(=X)(-Y-R'), $S(=Z)_{1-2}(-Y-R')$, in which Z is O, X is O, S or NH, and Y is O, S or NH, wherein at least one R is a sterically bulky group. Preferred bulky groups contain 3 non-hydrogen atoms or more, most preferred bulky groups contain 6 non-hydrogen atoms or more and are preferably cyclic and/or aromatic. It will be apparent from the description of this invention that these preferred definitions apply to the case wherein at least one R substituent is different from hydrogen. In case 2 or more R groups are bulky, the spatial requirements for achieving inhibition may be reduced, for example, from 6 atoms to 3 atoms.

It is preferred that R groups are acyl groups, especially aromatic acyl groups. It is especially preferred that the acyl groups be bound to a nitrogen atom at position 4 of a pyrimidine base. An especially preferred acyl group is the benzoyl group.

R' is preferably selected from H; alkyl, alkenyl or alkynyl (each having from 1-50 C atoms); aryl, naphthyl, biphenyl or tolyl (each having from 6-50 C atoms). These groups may be straight or branched chain, symmetric or asymmetric, chiral or achiral, and may contain one or more heteroatoms selected from N, NH, S and O, and may also comprise fused aromatic systems. R' may be heterocyclic, including pyridyl, imidazolyl, pyrimidinyl, pyridazinyl, quinolyl, acridinyl, imidazolyl, pyrrolyl, furanyl, thienyl, isoxazolyl, oxazolyl, thiazolyl or biotinyl and may be bound or fused to any available position.

R' may be substituted, preferentially with one or more lower organic groups (up to 10 carbon-atoms) or derivatives thereof which enhance the triplex inhibiting effect or are otherwise useful herein. These may be groups such as alkyl, alkenyl, alkynyl, aryl, naphthyl, biphenyl, tolyl, benzyl, and groups such as -NO, $-NO_2$, $-SO_3$, -CN, -OH, -SH, $-PO_3^{2-}$, -COOH, -F, -Cl, -Br, and -I.

Compounds of the present invention can be conveniently prepared according to the methods described in WO 92/20702. An especially preferred method of synthesis uses, in a first step, the synthesis of the base substituted by the sterically bulky substituent, preferably having also attached a reactive group and/or a linker moiety for attachment of the modified base to a monomeric backbone unit, for example, protected N-aminoethylglycine. In a second step, bases are attached via the linker moiety to a nitrogen atom at the preformed and protected monomeric backbone unit. In a third step, the base-containing monomer is prepared for oligomerization with other bases containing monomeric backbone units or an already formed oligomer, *e.g.* cleaving of protecting groups at one end of the backbone

unit and/or activating this end for oligomerization. In a fourth step, the base-containing monomers are oligomerized depending upon the sequence requirements for complementarity for duplex formation with a complementary nucleic acid.

Preferred monomeric backbone units that may be protected with a protecting group appropriate for the active groups during synthesis of the monomeric backbone unit are compounds of the general formula:



wherein:

R^1 is C_1-C_4 alkyl substituted by -$COOP^1$, -NHP^1, -OP^1 or SP^1, wherein P^1 is hydrogen or a protecting group;

R^2 is C_1-C_4 alkyl substituted by -$COOP^2$, -NHP^2, -OP^2 or SP^2, wherein P^2 is hydrogen or a protecting group;

M is a naturally or non-naturally occurring heterocyclic moiety bound by a linker to nitrogen, said linker being 1-3 atoms in length; and

R^3 is a sterically bulky substituent containing at least 3 or more non-hydrogen atoms.

Monomers which are not substituted by R^3 are disclosed in WO 92/20702. In a preferred case, R^1 contains the group -$COOP^1$ and R^2 contains the group -NHP^2, wherein the protecting groups (P^1 and P^2) are cleavable under different reaction conditions from each other.

For example, in certain preferred embodiments, peptide nucleic acid backbones may be employed. Such backbones have the general formula (I):



(I)

wherein:

n is at least 2,

each of L^1-L^n is independently selected from the group consisting of hydrogen, hydroxy, $(C_1$-$C_4)$alkanoyl, naturally occurring nucleobases, non-naturally occurring nucleobases, aromatic moieties, DNA intercalators, nucleobase-binding groups, heterocyclic moieties, and reporter ligands, at least one of L^1-L^n being a naturally- or non-naturally-occurring nucleobase substituted with a sterically bulky group as described herein;

each of C^1-C^n is $(CR^6R^7)_y$ where R^6 is hydrogen and R^7 is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or R^6 and R^7 are independently selected from the group consisting of hydrogen, $(C_2$-$C_6)$alkyl, aryl, aralkyl, heteroaryl, hydroxy, $(C_1$-$C_6)$alkoxy, $(C_1$-$C_6)$alkylthio, NR^3R^4 and SR^5, where R^3 and R^4 are as defined above, and R^5 is hydrogen, $(C_1$-$C_6)$alkyl, hydroxy-, alkoxy-, or alkylthio- substituted $(C_1$-$C_6)$alkyl, or R^6 and R^7 taken together complete an alicyclic or heterocyclic system;

each of D^1-D^n is $(CR^6R^7)_z$ where R^6 and R^7 are as defined above;

each of y and z is zero or an integer from 1 to 10, the sum y + z being greater than 2 but not more than 10;

each of G^1-G^{n-1} is $-NR^3CO-$, $-NR^3CS-$, $-NR^3SO-$ or $-NR^3SO_2-$, in either orientation, where R^3 is as defined above;

each pair of A^1-A^n and B^1-B^n are selected such that:

(a) A is a group of formula (IIa), (IIb) or (IIc) and B is N or R^3N^+; or

(b) A is a group of formula (IId) and B is CH;



(IIa)



(IIb)



(IIc)



(IId)

where:

X is O, S, Se, NR^3, CH_2 or $C(CH_3)_2$;

Y is a single bond, O, S or NR^4;

each of p and q is zero or an integer from 1 to 5, the sum p+q being not more than 10;

each of r and s is zero or an integer from 1 to 5, the sum r+s being not more than 10;

each R^1 and R^2 is independently selected from the group consisting of hydrogen, (C_1-C_4)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen;

each of G^1-G^{n-1} is $-NR^3CO-$, $-NR^3CS-$, $-NR^3SO-$ or $-NR^3SO_2-$, in either orientation, where R^3 is as defined above;

Q is $-CO_2H$, $-CONR'R''$, $-SO_3H$ or $-SO_2NR'R''$ or an activated derivative of $-CO_2H$ or $-SO_3H$; and

I is $-NHR'''R''''$ or $-NR'''C(O)R''''$, where R', R", R''' and R'''' are independently selected from the group consisting of hydrogen, alkyl, amino protecting groups, reporter ligands, intercalators, chelators, peptides, proteins, carbohydrates, lipids, steroids, oligonucleotides and soluble and non-soluble polymers.

In certain embodiments, at least one A is a group of formula (IIc) and B is N or R^3N^+. In other embodiments, A

is a group of formula (IIa) or (IIb), B is N or R^3N^+, and at least one of y or z is not 1 or 2.

Some preferred peptide nucleic acids have general formula (IIIa) or (IIIb):



(IIIa)



(IIIb)

wherein:

each L is independently selected from the group consisting of hydrogen, phenyl, heterocyclic base moieties, including those substituted with a sterically bulky group or groups, naturally occurring nucleobases, and non-naturally occurring nucleobases;

each $R^{7'}$ is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids;

n is an integer from 1 to 60;

each of k, l, and m is independently zero or an integer from 1 to 5;

p is zero or 1;

R^h is OH, NH_2 or -NHLysNH$_2$; and

R^i is H or $COCH_3$.

Particularly preferred are compounds having formula (IIIa) or (IIIb) wherein each L is independently selected from the group consisting of the nucleobases thymine (T), adenine (A), cytosine (C), guanine (G) and uracil (U), especially where one or more are modified with a sterically bulky substituent in accordance with this invention, k and m are zero or 1, and n is an integer from 1 to 30, in particular from 4 to 20.

The peptide nucleic acids of the invention can be synthesized by adaptation of standard peptide synthesis procedures, either in solution or on a solid phase. The synthons used are specially monomer amino acids or their activated derivatives, protected by standard protecting groups. The oligonucleotide analogs also can be synthesized by using the corresponding diacids and diamines.

Thus, monomer synthons useful for incorporation into PNA of the preceding formulae include those selected from the group consisting of amino acids, diacids and diamines, having general formulae:



(IV) (V) (VI)

wherein L, A, B, C and D are as defined above, except that any amino groups therein may be protected by amino protecting groups; E is COOH, CSOH, SOOH, SO_2OH or an activated derivative thereof; and F is NHR^3 or $NPgR^3$, where R^3 is as defined above and Pg is an amino protecting group.

Preferred monomer synthons according to the invention include those having formula (VIIIa)-(VIIIc):



(VIIIa)



(VIIIb)



(VIIIc)

or amino-protected and/or acid terminal activated derivatives thereof, wherein L is selected from the group consisting of hydrogen, phenyl, heterocyclic moieties, naturally occurring nucleobases, and non-naturally occurring nucleobases; and $R^{7'}$ is selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids.

Also useful in the present invention are chiral PNA backbones. Such backbones are preferably derived from two or more monomers, at least one of which contain a aliphatic cyclic structure. Representative of such monomers are those of formula:



wherein:

B is a naturally or non-naturally occurring nucleobase which may be substituted with a sterically bulky group in accordance with this invention;

at least one of Cα or Cβ is in the S configuration;

and

n is 0, 1, 2, or 3.

In preferred embodiments Cα and Cβ are in the S configuration. In further preferred embodiments of the invention B is adenine, cytosine, guanine, thymine, or uracil. In more preferred embodiments n is 2.

In further preferred embodiments the peptide nucleic acid oligomers contain at least one peptide nucleic acid monomer having a (2-aminoethyl)glycine backbone with a chiral center in the ethyl portion of the backbone. The monomer is incorporated into peptide nucleic acid oligomers at a position corresponding to a region of variability in the target molecule.

One nucleic acid mimic can contain one or more nucleobases modified as described above. It was found that increasing the number of nucleobases containing sterically bulky substituents within one nucleic acid mimic inhibited triplex formation while retaining the ability to form duplexes.

In order to achieve the inhibition of triplex formation, the nucleic acid mimic and the position of attachment of the sterically bulky group are chosen such that the heterocyclic bases to which the sterically bulky substituent is attached would be located in close proximity to each other when bound to the nucleic acid, were a triplex to form. Preferably the substituted bases on the nucleic acid mimics should, in the hypothetical triplex, be located on the same side, *i.e.* base pairing to the same nucleobase of the nucleic acid strand. This case wherein the substituted bases of the mimic would base pair to the same base on the nucleic acid strand will be termed as "opposed". That the substituted bases would have to base pair with a

predefined base on the nucleic acid strand can be achieved by choosing the base sequence and orientation of the mimics such that only the triplex formation could occur in a way which is inhibited by the use of the sterically bulky substituents.

The compounds of the present invention can be used in methods for the determination of a nucleic acid comprising a nucleic acid mimic substituted at positions which are 1, 2 or 3 atoms removed from the atom of the base which is attached to the backbone, incubating said nucleic acid mimics and said nucleic acid under conditions suitable for the formation of a duplex between said nucleic acid mimic and said nucleic acid and determining the occurrence of said duplex as a measure of the occurrence of said nucleic acid. These methods are believed to function according to the principles described in WO 92/20703 (herein incorporated by reference) by replacing the compounds used in the prior art with the compounds described herein above. It is especially preferred to use a nucleic acid mimic which is labeled with a reporter group either at one of the termini of the nucleic acid mimic or at any position of the backbone or the base moieties. A reporter group according is a group that can be detected, for example a fluorescent group like fluorescein, or one which can be detected by a further compound which is bound in a subsequent step to the reporter group. For example, if the sterically bulky substituent is a biotin group or a group containing a biotin group, the nucleic acid mimic, and thereby the nucleic acid can be determined by adding detectable streptavidin to the hybrid. It is preferred to remove any excess biotin-labeled nucleic acid mimic from the mixture prior to this incubation. The reporter group is then detected by means which are known to the art-skilled.

The present invention is suitable for detection of expression of a disease-causing protein in a cell or tissue sample from patients who have a disease state. A number of assays may be formulated for the inhibition of protein

expression employing the present invention, which assays will commonly comprise contacting a cell or tissue sample with a nucleic acid mimic of the invention under conditions selected to permit detection, and usually quantitation, of such inhibition. As described below, fluorescein-labeled nucleic acid mimics are prepared and contacted with a cell or tissue sample suspected of expression of a disease-causing protein. The sample is then washed to remove unbound nucleic acid mimic. Fluorescence remaining in the sample, detected and quantitated by fluorimetry, indicates bound nucleic acid mimic (which in turn indicates the presence of nucleic acid encoding the disease-causing protein).

The compounds of the present invention may be useful in binding to target molecules. Target molecules of the present invention can include any of a variety of biologically significant molecules. Such target molecules may be nucleic acid strands such as significant regions of DNA or RNA which encode proteins that may be responsible for causing and/or maintaining a disease state in mammals. Such other target molecules may be transcription factors. Target molecules can be carbohydrates, glycoproteins or other proteins. In some preferred embodiments, the target molecule can be a protein such as an immunoglobulin, receptor, receptor binding ligand, antigen or enzyme, and more specifically can be a phospholipase, tumor necrosis factor, endotoxin, interleukin, plasminogen activator, protein kinase, cell adhesion molecule, lipoxygenase, hydrolase or transacylase. In other embodiments of the invention, the target molecule may be an important region of the human immunodeficiency virus, *Candida*, herpes viruses, papillomaviruses, cytomegalovirus, rhinoviruses, hepatitis viruses or influenza viruses. In yet other embodiments of the invention, the target molecule may be a region of an oncogene.

The following examples further illustrate the invention and are not intended to limit the same.

EXAMPLES

EXAMPLE 1

A. Exemplary General Syntheses

Phosphoramidates were purchased from Cruachem (UK) and the DNA oligomers were assembled on a MilliGen/Biosearch 8700 DNA synthesizer. The A, C, G and T PNA monomers were purchased from Biosearch (USA). N'-Boc-aminoethyl glycine was purchased from Biosearch (USA). All PNA oligomers were synthesized on a custom-made PNA synthesizer (Biosearch, USA) by a modified Merrifield method (Christensen, L., Fitzpatrick, R., Gildea, B., Warren, B. and Coull, J. (1994), Innovations and Perspectives in Solid Phase Synthesis, R. Epton, Ed., SPCC (UK) Ltd., Oxford, England; Christensen et al., (1995), **J. Pep. Sci.**, *3*, 175) and purified by reverse phase-HPLC. The PNA oligomers were characterized by $FAB^{+}MS$.

B. T_m Measurements

Absorbance versus temperature was measured at 260 nm using a Guilford Response spectrophotometer. Heating rate was 0.5°C/min from 5-90°C. PNA oligomers were hybridized with complementary DNA sequences in a medium salt buffer containing 100 mM NaCl, 10 mM sodium phosphate and 0.1 mM EDTA, pH was adjusted to 5, 7 or 9, as desired. The samples were heated to 90°C for 5 min, slowly cooled to 20° and left at 4°C for 30 min prior to T_m measurements.

C. Synthesis of modified cytosine monomer

(i) Benzoyl cytosin-1-ylacetate (1)

Reference is made to Figure 1 where to cytosine (20 g, 0.18 mol) in 400 mL DMF was added 7.2 g (0.18 mmol) of NaH (disp. in oil 60%). The mixture was heated to 50°C and stirred for 2 h under nitrogen. After cooling to room temperature, 29 mL (1.1 eq.) of benzyl bromoacetate was added over 2 h. After stirring overnight, the dark suspension was filtered and the filtrate washed with cold DMF and 0.2 M sodium bicarbonate. The product (1) was crystallized from ethanol. Yield: 37 g (79%). ^1H NMR (d_6-

DMSO): δ 4.56 (s, 2 H, CH_2O), 5.24 (s, 2 H, CH_2CO), 5.77 (d, 1 H, H_5), 7.20 (dd, 2 H, NH_2), 7.45 (m, 5 H, aromatic), 7.65 (d, 1 H, H_6). MS (FAB) m/z 260 $(M+H)^+$ (calcd 260).

(ii) (N^4-(Benzoyl)cytosin-1 yl)acetic Acid (2)

To a solution of (1) (10 g, 38 mmol) in 10 mL pyridine was added 6.6 g (47 mmol) of benzoyl chloride and stirred overnight at room temperature. The solution was evaporated under reduced pressure. The residue was dissolved in 1 M KOH and stirred for 3 h after which the Ph was adjusted to 2 with conc. HCl. The target compound (2) precipitated out. Yield: 9.3 g (90%). ^1H NMR (d_6-DMSO): δ 4.59 (s, 2 H, CH_2O), 7.31 (d, 1 H, H_5), 7.5-8.2 (7 H, aromatic, NH, H_6). MS (FAB) m/z 273 $(M+H)^+$ (calcd 273).

(iii) N-((N^4-(Benzoyl)cytosin-1-yl)acetyl)-N-(2-Bocaminoethyl)glycine (3)

4.8 g (22 mmol) of Methyl N-(2-Boc-aminoethyl)-glycinate (2), 2.4 g (14.7 mmol) of benzyloxycarbonyl chloride, 2.9 g (14.9 mmol) of DCC and 2.4 g (14.7 mmol) of DhBtOH was dissolved in 50 mL of DMF and stirred for 4 h at room temperature. Dichloromethane (100 mL) was added and the mixture extracted with 3 x 0.2 M sodium bicarbonate, 2 x 1 M sodium hydrogen sulfate and brine. The organic phase was dried with magnesium sulfate and evaporated to dryness under reduced pressure. The residue was dissolved in 2 M KOH and stirred for 1 h after which the pH was adjusted to 2 with 1 M HCl, whereby the target compound precipitated. The product (3) was crystallized from methanol: ethyl acetate: hexane (1:2:2). Yield: 4.2 g (60%). ^1H NMR (d_6-DMSO): δ 1.45 and 1.47 (d, 9 H, Boc), 3.28-3,53 (m, 4 H, CH_2), 4.08 and 4.31 (s, 2 H, CH_2CO), 4.75 and 4.95 (s, 2 H, CH_2CO), 6.83 and 7.03 (m, 1 H, BocN*H*), 7.38 (m, 1 H, H_5), 7.57-8.10 (m, 6 H, aromatic and H_6). MS (FAB) m/z 474 $(M+H)^+$ (calcd 474).

EXAMPLE 2

Triplex inhibition

The effect of the benzoylated cytosine (C^{Bz}) residue on the hybridization properties of a homopyrimidine peptide nucleic acid was studied. PNA1, H-TTTTCCTCTC-LysNH$_2$, was synthesized containing either C^{Bz} in position 6 (PNA2), or two C^{Bz} residues in positions 6 and 8 (PNA3) or in positions 5 and 6 (PNA4). These PNAs were hybridized to a complementary oligonucleotide in the parallel (ODN1) or the antiparallel (ODN2) configuration and the thermal stability (T_m) of the resulting complexes was determined at pH 5, 7, and 9. The results are set forth in Table 1. Absorbance versus temperature curves were measured at 260 nm in 100 mM NaCl, 10 mM sodium phosphate and 0.1 mM EDTA. Heating rate: 0.5°/minute at 5-90°C. The T_ms in parentheses were obtained by cooling from 90° to 10°C while measuring the absorbance at 260 nm.

TABLE 1

Melting temperatures T_m (°C) for binding of PNA to single stranded homopurine DNA oligomer.

Sequence	pH	ODN1	ODN1
PNA1	5	>85.0	69.5
	7	58.5 (31.0)	40.5
	9	26.0	33.5
PNA2	5	56.0 (38.0)	54.0 (42.5)
	7	27.0 (20.0)	32.0 (29.0)
	9		31.0 (29.0)
PNA3	7	28.0	33.0
PNA4	7	26.0	32.5

Oligodeoxynucleotides:

ODN1 = 5'-AAAAGGAGAG-3'; Seq. ID No: 1

ODN2 = 5'-GAGAGGAAAA-3'; Seq. ID No: 2

Nucleic acid mimics:

PNA1 = H-TTTTCCTCTC-LysNH_2; Seq. ID No: 3

PNA2 = H-TTTTCC^{Bz}TCTC-LysNH_2; Seq. ID No: 4, where C^{Bz} is N

PNA3 = H-TTTTCC^{Bz}TC^{Bz}TC-LysNH_2; Seq. ID No: 5, where C^{Bz} is N

PNA4 = H-TTTTC^{Bz}C^{Bz}TCTC-LysNH_2; Seq. ID No: 6, where C^{Bz} is N

Unmodified PNA1 exhibited expected behaviour. First, pronounced pH dependence was observed which is compatible with PNA_2-DNA triplex formation requiring cytosine protonation. Second, the parallel complex showed highest stability at pH 5 and 7, but not at pH 9. These results suggest that triplexes are the most stable complexes at pH 5 and 7, while the (antiparallel) duplex is more stable at pH 9. Triplex formation at pH 7 is also consistent with pronounced hysteresis ($\approx$ 27°C) observed at this pH.

PNA2, containing one C^{Bz} residue, apparently also formed a triplex at pH 5 as judged by the hysteresis, but the T_m was lower ($\approx$ 30°C) than that of the PNA1 complex. Thus, the benzoyl groups do indeed appear to interfere with efficient triplex formation. This effect is especially pronounced at pH 7. Only slight hysteresis is observed and notably the antiparallel complex shows higher stability which does not decrease at more alkaline conditions (pH 9). These results strongly argue in favour of the duplex being the most stable complex at pH 7 with this PNA.

The complexes with PNA1 and PNA2 showed equal thermal stability at pH 9, *i. e.* for the duplex, thus indicating that the C^{Bz} residue does not interfere with Watson-Crick base pairing in the PNA-DNA duplex. This conclusion was supported by experiments with a C^{Bz} containing mixed purine/pyrimidine sequence using the PNA oligomers H-AGT CAC CTA C-LysNH_2 (PNA5) and H-AGT CA C^{Bz} CTA C-LysNH_2 (PNA6), and is set forth in Table 2. Absorbance versus temperature curves were measured at 260 nm in 100 mM NaCl, 10 mM sodium phosphate and 0.1 mM EDTA, at pH 7. Heating rate: 0.5%/min at 5-90°C. The T_ms in parentheses were obtained by cooling from 90 to 10°C while measuring the

absorbance at 260 nm. The hysteresis of the system is the difference between the T_m (10-90°) and T_m (90-10°).

TABLE 2

Melting temperatures T_m (°C) for binding of PNA in duplex mode to single-stranded DNA oligomer.

	PNA5	PNA6
ODN3	49 (48)	50
ODN4	33 (31)	34

Oligodeoxynucleotides:

ODN3 = 5'-GTAGGTCACT-3'; Seq. ID No: 7

ODN4 = 5'-GTAGATCACT-3'; Seq. ID No: 8

Nucleic acid mimics:

PNA5 = H-AGTCACCTAC-LysNH_2; Seq. ID No: 9

PNA6 = H-AGTCAC^{Bz}CTAC-LysNH_2; Seq. ID No: 10, where C^{Bz} is N

Both of these oligomers form highly stable duplexes with their antiparallel oligonucleotide target. The stoichiometry of these complexes was determined by Job-plots as 1:1 complexes in both cases. The insignificant difference in T_ms of the complexes between PNA5 and PNA6 with ODN3 falls within experimental error and can be interpreted as evidence of the structure shown in Figure 2, by which the benzoyl group is positioned in the major groove not interfering with the Watson-Crick base pairing. This is also in full agreement with the (G→A) mismatch positioned opposite the cytosine in the DNA strand, giving rise to a drop in T_m of 15-16° for both PNA5 and PNA6. An important feature distinguishing duplexes from triplexes under the experimental conditions is the very small hysteresis (less than 2°) obtained with duplexes when going from high to low temperature, whereas PNA:DNA triplexes showed pronounced hysteresis typically in the range of 20-30° (Table 2). This is also evident for the complexes between PNA6 and ODN3 or ODN4 in which a hysteresis of 1-2°C was observed. The small

hysteresis obtained with PNA6 also indicated that the benzoyl group does not interfere significantly with the binding kinetics.

EXAMPLE 3

Coupling of nucleic acid mimic to fluorescein

A nucleic acid mimic having a free amine moiety is dissolved in THF:H_2O to provide a solution that is 0.1 M of nucleic acid mimic. To the nucleic acid mimic solution is added fluorescein isothiocyanate, providing a solution that is 0.1-1.0 M in fluorescein isothiocyanate. The resultant reaction mixture is stirred for 0.1-2 hours and concentrated under reduced pressure. The residue is purified by preparative HPLC.

EXAMPLE 4

Detection of mutant β-amyloid precursor protein gene expression (βAPP)

Point mutations in the gene encoding β-amyloid have been implicated in familial Alzheimer's disease (FAD). Nucleic acid mimics are labeled with fluorescein or other fluorescent tags, as illustrated in Example 3 above. The fluorescently-labeled nucleic acid mimics are contacted with a cell or tissue sample suspected of abnormal βAPP expression under conditions suitable for specific hybridization of the nucleic acid mimic to the nucleic acid encoding abnormal βAPP. The sample is then washed to remove unbound nucleic acid mimics. Label remaining in the sample indicates bound nucleic acid and is quantitated using a fluorimeter, fluorescence microscope or other routine means.

A first sample of cells or tissues suspected of expressing a point mutation in the βAPP gene is incubated with a fluorescein-labeled nucleic acid mimic which is targeted to the mutant codon 717, codon 670 or codon 671 of the βAPP mRNA. A second identical sample of cells or tissues is incubated with a second labeled nucleic acid

mimic which is targeted to the same region of normal βAPP mRNA under conditions in which specific hybridization can occur. The sample is then washed to remove unbound nucleic acid mimic. Label remaining in the sample indicates bound nucleic acid and is quantitated using a fluorimeter or other routine means. The presence of mutant βAPP is indicated if the first sample retains labeled nucleic acid mimic and the second sample does not retain labeled nucleic acid mimic.

EXAMPLE 5

Detection of mutant H-*ras* gene expression

Point mutations in the H-*ras* gene have been implicated in numerous aberrations of the *ras* pathway. Nucleic acid mimics are labeled with fluorescein or other fluorescent tags as illustrated in Example 3 above. Labeled nucleic acid mimics are contacted with cell or tissue samples suspected of abnormal *ras* expression under conditions in which specific hybridization can occur. The sample is then washed to remove unbound labeled nucleic acid mimic. Label remaining in the sample indicates bound nucleic acid (*i.e.* that which encodes for mutant *ras*) and is quantitated using a fluorimeter, fluorescence microscope or other routine means.

A first cell or tissue sample suspected of expressing a point mutation in the H-*ras* gene is incubated, under conditions suitable for specific hybridization, with a fluorescein-labeled nucleic acid mimic which is targeted to codon 12, codon 13 or codon 61 of mutant H- *ras* mRNA. A second identical sample of cells or tissues is incubated, under conditions suitable for specific hybridization, with a second fluorescently-labeled nucleic acid mimic which is targeted to the same region of normal H-*ras* mRNA. The samples are then washed to remove unbound labeled nucleic acid mimics. Label remaining in the sample indicates bound nucleic acid and is quantitated using a fluorimeter or other routine means. The presence of mutant H-*ras* is indicated if

the first sample exhibits fluorescence but the second sample does not.

EXAMPLE 6

Inhibition of gene expression by nucleic acid mimics

A preferred assay to test the ability of nucleic acid mimics to inhibit expression of the E2 mRNA of papillomavirus is based on the well-documented transactivation properties of E2. Spalholtz *et al.*, J. Virol., *61*, 2128 (1987). A reporter plasmid (E2RE1CAT) is constructed to contain the E2 responsive element, which functions as an E2-dependent enhancer. E2RE1CAT also contains the SV40 early promoter, an early polyadenylation signal and the chloramphenicol acetyl transferase (CAT) gene. Within the context of this plasmid, CAT expression is dependent upon expression of E2. The dependence of CAT expression upon the presence of E2 is tested by transfection of this plasmid into C127 cells transformed by BPV-1, uninfected C127 cells and C127 cells cotransfected with E2RE1CAT and an E2 expression vector.

A. Inhibition of BPV-1 E2 expression: BPV-1 transformed C127 cells are plated in 12-well plates. Twenty four hours prior to transfection with E2RE1CAT, cells are pretreated by the addition of complementary nucleic acid mimic to the growth medium at a final concentrations of 5, 15 and 30 mM. The next day, cells are transfected with 10 μg of E2RE1CAT by calcium phosphate precipitation. E2RE1CAT (10 μg) and carrier DNA (PUC 19, 10 μg) are mixed with 62 μL of 2 M $CaCl_2$ in a final volume of 250 μL of H_2O, followed by the addition of 250 μL of 2X HBSP (1.5 mM Na_2PO_4, 10 mM KCl, 280 mM NaCl, 12 mM glucose and 50 mM HEPES, pH 7.0) and incubated at room temperature for 30 minutes. This solution (100 μL) is added to each test well and allowed to incubate for 4 hours at 37°C. After incubation, the cells are glycerol shocked for 1 minute at room temperature with 15% glycerol in 0.75 mM Na_2PO_4, 5 mM KCl, 140 mM NaCl, 6 mM glucose and 25 mM HEPES, pH 7.0. After shocking, the cells

are washed 2X with serum-free DMEM and refed with DMEM containing 10% fetal bovine serum and nucleic acid mimic at the original concentration. Forty eight hours after transfection, the cells are harvested and assayed for CAT activity.

For determination of CAT activity, cells are washed 2X with phosphate-buffered saline and collected by scraping. Cells are suspended in 100 μL of 250 mM Tris-HCl, pH 8.0, and disrupted by freeze-thawing three times. This cell extract (25 μL) is used for each assay.

For each assay, the following are mixed together in a 1.5 mL Eppendorf tube and incubated at 37°C for one hour: 25 μL of cell extract, 5 μL of 4 mM acetyl coenzyme A, 18 μL of H_2O and 1 μL of ^{14}C-chloramphenicol, 40-60 mCi/mM. After incubation, chloramphenicol (acetylated and non-acetylated forms) is extracted with ethyl acetate and evaporated to dryness. Samples are resuspended in 25 μL of ethyl acetate, spotted onto a tlc plate and chromatographed in chloroform:methanol (19:1). The chromatographs are analyzed by autoradiography. Spots corresponding to acetylated and non-acetylated ^{14}C-chloramphenicol are excised from the tlc plate and counted by liquid scintillation for quantitation of CAT activity. Nucleic acid mimics that depress CAT activity in a dose-dependent manner are considered to have a positive effect.

B. Inhibition of HPV E2 expression: The assay for inhibition of human papillomavirus (HPV) E2 by nucleic acid mimics is essentially the same as that for BPV-1 E2. For HPV assays, appropriate HPVs are cotransfected into either CV-1 or A431 cells with PSV2NEO using the calcium phosphate method described above. Cells which take up DNA are selected for culturing in media containing the antibiotic G418. G418-resistant cells are then analyzed for HPV DNA and RNA. Cells expressing E2 are used as target cells for complementary studies. For each nucleic acid mimic, cells are pretreated as above, transfected with E2RE1CAT and analyzed for CAT activity as described above.

Nucleic acid mimics are considered to have a positive effect if they can depress CAT activity in a dose-dependent manner.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Nielson, Peter E. Et al.

(ii) TITLE OF INVENTION: Substituted Nucleic Acid Mimics

(iii) NUMBER OF SEQUENCES: 10

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Woodcock Washburn et al.

(B) STREET: One Liberty Place 46th. Floor

(C) CITY: Philadelphia

(D) STATE: PA

(E) COUNTRY: USA

(F) ZIP: 19103

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: N/A

(B) FILING DATE: Herewith

(C) CLASSIFICATION:

(vii) Prior Application Data:

(A) US Application Serial No.: 08/612,661

(B) 08-MAR-1996

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Caldwell, John W

(B) REGISTRATION NUMBER: 28,937

(C) REFERENCE/DOCKET NUMBER: ISIS-2425

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 215-568-3100

(B) TELEFAX: 215-568-3439

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAAAGGAGAG 10

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GAGAGGAAAA 10

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: PNA

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: PNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TTTTCCTCTC 10

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: PNA

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: PNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TTTTCNTCTC 10

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: PNA

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: PNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TTTTCNTNTC 10

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: PNA

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: PNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TTTTNNTCTC 10

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GTAGGTCACT 10

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GTAGATCACT 10

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: PNA

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: PNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AGTCACCTAC 10

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: PNA

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: PNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

AGTCANCTAC 10

CLAIMS

What is claimed is:

1. A nucleic acid mimic comprising a non-naturally occurring backbone structure to which are appended a plurality of heterocyclic bases,

at least one of said bases being substituted with at least one sterically bulky substituent at a position one, two or three atoms removed from the position of attachment of said base to the backbone.

2. The nucleic acid mimic according to claim 1 wherein said sterically bulky substituent is -R', -OR', -SR', $-N(R')_2$, $-C(R')_3$, -C(= X)(R'), -C(= X) (-Y-R') or $S(=O)_{1-2}$(-Y-R') wherein:

X is O, S or NH;

Y is O, S or NH; and

wherein R' comprises at least 3 atoms and is H, C_1-C_{50}-alkyl, C_2-C_{50}-alkenyl, C_2-C_{50}-alkynyl, C_7-C_{50}-alkyl-aryl, C_6-C_{50}-aryl, C_{10}-C_{50}-naphthyl, C_{12}-C_{50}-biphenyl, C_7-C_{50}-aryl-alkyl, pyridyl, imidazolyl, pyrimidinyl, pyridazinyl, quinolyl, acridinyl, pyrrolyl, furanyl, thienyl, isoxazolyl, oxazolyl, thiazolyl and biotinyl, wherein R' can be substituted one or more times by -NO, $-NO_2$, $-SO_3^-$, -CN, -OH, $-NH_2$, -SH, $-PO_3^{2-}$, -COOH, -F, -Cl, -Br and -I.

3. The nucleic acid mimic according to claim 1 wherein said base is a naturally or non-naturally occurring pyrimidine base.

4. The nucleic acid mimic according to claim 3 wherein said sterically bulky substituent is bound to C-6, C-5 or N-4 of said naturally occurring pyrimidine base.

5. The nucleic acid mimic according to claim 4 wherein said sterically bulky substituent is bound to N-4 of said naturally occurring pyrimidine base.

6. The nucleic acid mimic according to claim 5 wherein said naturally occurring pyrimidine base is cytosine.

7. The nucleic acid mimic according to claim 5 wherein said sterically bulky substituent is (C=O)-R'' wherein R'' is C_1-C_{20}-alkyl or C_6-C_{18}-aryl.

8. The nucleic acid mimic according to claim 7 wherein said sterically bulky substituent is (C=O)-C_6H_5.

9. A method for the determination of a nucleic acid comprising:

providing a nucleic acid mimic;

incubating said nucleic acid mimic and said nucleic acid under conditions suitable for the formation of a duplex between said nucleic acid mimic and said nucleic acid; and

determining the occurrence of said duplex as a measure of the occurrence of said nucleic acid;

said nucleic acid mimic comprising a non-naturally occurring backbone structure to which are appended a plurality of heterocyclic bases,

at least one of said bases being substituted with at least one sterically bulky substituent at a position one, two or three atoms removed from the position of attachment of said base to the backbone.

10. A compound for the preparation of a nucleic acid mimic having the general formula:



wherein:

R^1 is C_1-C_4-alkyl having at least one $-COOP^1$, $-NHP^1$, $-OP^1$ or $-SP^1$ group; P^1 is hydrogen or a protecting group;

R^2 is C_1-C_4 alkyl substituted by $-COOP^2$, $-NHP^2$, $-OP^2$ or $-SP^2$, wherein P^2 is hydrogen or a protecting group;

M is a naturally or non-naturally occurring heterocyclic moiety bound to N by a one to three carbon linker; and

R^3 is a sterically bulky substituent containing 3 or more non-hydrogen atoms.



FIGURE 1



FIGURE 2

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/03584

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07H 21/00
US CL :536/22.1
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6; 436/501; 530/300, 350; 514/2, 44; 536/22.1, 23.1, 24.1, 24.3, 24.31, 24.32, 24.33, 25.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	Christensen et al., "Solid-phase Synthesis of Peptide Nucleic Acids", Journal of Peptide Science, 1995, Vol. 3, pages 175-183, see especially the abstract and Figures 1 and 2.	1-8, 10 ------- 9
X --- Y	WO 92/20703 A1 (BUCHARDT et al.) 26 November 1992, see especially the Abstract and Figures 15 and 16.	1-8, 10 ---------- 9
X --- Y	WO 86/05518 A1 (SUMMERTON et al.) 25 September 1986, see especially the Abstract and Example 2 on pages 53-57.	1-8 , 10 ---------- 9

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
07 JUNE 1997	02 JUL 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer ARDIN MARSCHEL Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/03584

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	WO 92/20702 A1 (BUCHARDT et al.) 26 November 1992, see especially the Abstract and Figures 4-6.	1-8, 10 ---------- 9
Y	US 4,828,979 A (KLEVAN et al.) 09 May 1989, see especially Figures 1-4 and column 5, lines 17-37.	1-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/03584

B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

APS, DIALOG covering CAS, BIOTECH ABS, WPI, EMBASE, MEDLINE using keywords; mimic, hybridiz?, complement?, antisense, steric, bulky, fluorescen?, label?